The development of our ground breaking high-throughput Encapsulated Nanoscale Crystallization technology (ENaCt) will continue via a Newcastle University-based PhD CASE award with AstraZeneca. The aim of the project is to ‘control’ the solid form of new drug-like molecules to have improved bioavailability and physical properties.
More details can be found on the Newcastle University website:
Indicatrix CEO Dr Michael Hall delivering a presentation on Encapsulated Nanodroplet Crystallisation experiments for the Winter 2020 ABX Antibiotic Discovery meeting held at the University of Plymouth. The talk covers the general concept of ENaCt as well as it’s development and features some nice examples which have been worked on by the team at Newcastle University.
The impact of Indicatrix’s patent pending ENaCt technology on the potential enchantment of drug development pipelines is highlighted in a new article in the European Pharmaceutical Review “New Technique to Grow Crystals from Nanoscale Droplets Developed”.
Indicatrix Crystallography welcomes to our newest team member Jake Weatherston.
Jake joins Indicatrix as an industrial PhD student position, in collaboration with Newcastle University, supported by the Intensive Industrial Innovation Programme (IIIP) and the European Regional Development Fund.
With plenty of industrial experience from his time at High Force Research Ltd and an MChem degree from Newcastle University, Jake will bring his expertise to bear developing new methods and industrial applications for our break-through Encapsulated Nanodroplet Crystallisation (ENaCt) technology.
We look forward to doing lots of great science together with Jake over the coming years.